gemcitabine

ClinicalJuly 31, 2026

Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated

The PANOVA-3 trial shows that Tumor Treating Fields combined with gemcitabine and nab-paclitaxel improves overall survival and progression-free survival in locally advanced pancreatic cancer patients.

Sponsor company

Recent signals(8)

Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated

Personalized Treatment Approach for Malignant Peritoneal Mesothelioma Under Investigation

Phase I Study of JS001sc in Advanced Nasopharyngeal Carcinoma Shows Focus on Safety and Tolerability

Sitagliptin Combined with Gemcitabine and Paclitaxel in PDAC Patients

NCI Study Evaluates Gemcitabine, Carboplatin, and Lenalidomide for Urothelial Cancer

Phase 1/2 Study of Gemcitabine/Nab-paclitaxel and Radiation in Advanced Pancreatic Cancer

Phase Ib/II Study of Becotatugvedotin with Gemcitabine in Advanced PDAC

Phase II/III Trial Compares Pre- and Post-Surgery Chemotherapy for Gallbladder Cancer

Upcoming milestones

Related catalysts(6)

Shanghai Junshi Bioscience Co., Ltd. — gemcitabine

— gemcitabine

— Gemcitabine

— gemcitabine

— gemcitabine

— gemcitabine

Indications

Therapeutic areas

Get signals before the market moves